Durect Corporation is a specialty pharmaceutical company focused on the development of pharmaceutical products based on its drug delivery technology platforms. The Company?s product pipeline consists of seven investigational drug candidates in clinical development, with one program the subject of a New Drug Application (NDA) with the United States Food and Drug Administration (FDA), one program in Phase III, two programs in Phase II and three programs in Phase I. The Company?s products candidates include Remoxy, POSIDUR, ELADUR, TRANSDUR-Sufentanil, ORADUR-based opioid, ORADUR-ADHD, Relday and other products. The Company's developments are focused on the application of its pharmaceutical systems technologies to products in a range of chronic and episodic disease areas, including pain, cent... (Source: SEC reports)
Competitor - 1/8
Which company is more competitive with DURECT Corporation?
CUPERTINO, Calif., Oct. 1, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today the appointment of Michael H. Arenberg to the position of Chief Financial Officer, effective October 15, 2018. [...]
CUPERTINO, Calif., Sept. 20, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Myriam Theeuwes has joined DURECT as Senior Vice President, Clinical Development. Â Dr. [...]